GET DAILY SIGNALSInfuSystem Holdings (INFU) Analysts See +19% Upside to $17.50 Target
Key Takeaways
- The central stock price target of $17.50 is the arithmetic mean of three verified analyst price targets reviewed for InfuSystem Holdings, Inc. (INFU), a U.S. healthcare services provider listed on NYSE American.
- With the latest verified price near $14.68, reaching the target would require a move of roughly 19%.
- The analyst range is wide, from $15.00 to $20.00, reflecting disagreement over how quickly the company's growth and margin story will play out.
- The strongest supporting factors are improving profitability, expansion in home infusion and oncology services, and a consensus rating of Strong Buy.
- The biggest risks are a relatively high valuation, small-cap volatility, customer concentration, and execution on near-term growth.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- You can also explore Trending AI Robots for automated trading ideas across the market.
Reviewing the Analyst Consensus
InfuSystem Holdings, Inc. (INFU) provides infusion pumps and related biomedical services for hospitals, oncology clinics, and home-based care across the United States and Canada. Three verifiable, current analyst price targets were reviewed to establish the central target: Roth MKM at $15.00 (raised from $14.00 in February 2026), Lake Street's Ben Haynor at $17.50 (reiterated in September 2026), and B. Riley Securities at $20.00 (raised from $12.00 in August 2026). The arithmetic mean of these three figures is $17.50, with a low-to-high range of $15.00 to $20.00.
All three analysts carry Buy ratings, and independent trackers from S&P Global and MarketBeat describe the aggregate as a Strong Buy. The spread between $15 and $20 is meaningful for a stock trading near $14.68, and it signals genuine divergence in how analysts value the company's growth trajectory rather than uniform conviction about the exact target. The $17.50 figure used here is a calculated average, not an officially published consensus figure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where INFU Stands Today and the Road Ahead
At a recent price of about $14.68, INFU trades just below its 52-week high of roughly $14.85. Reaching $17.50 implies about a 19% gain, which is a substantial move that would require the stock to break decisively into new all-time-high territory and hold there.
The path toward the target would most plausibly be driven by continued revenue expansion and margin improvement. Trailing twelve-month revenue is approximately $144 million, with diluted EPS (earnings per share) of about $0.44 and a trailing P/E (price-to-earnings) ratio in the low 30s. Analysts model full-year 2026 EPS near $0.46, rising toward roughly $0.57 for 2027. If earnings keep growing while the company demonstrates durable demand in its higher-margin service lines, the valuation could support a higher stock price over time.
Bullish Factors to Watch
Several factors could support the shares. The company has posted a pattern of earnings beats in recent quarters, and the consensus rating of Strong Buy reflects analyst confidence in the story. Growth in outsourced biomedical services and direct-to-patient home infusion aligns with a broader healthcare shift toward cost-effective, site-of-care flexibility. Rising gross margins and improving free cash flow give the business room to self-fund expansion. A supportive technical backdrop—shares up more than 60% year to date and near a 52-week high—indicates positive investor sentiment and momentum.
Key Risks on the Horizon
Several risks could stand in the way. At a trailing P/E in the low 30s, the stock already prices in meaningful growth, leaving less room for error if results disappoint. As a small-cap with a market value near $294 million, the shares are prone to sharp swings on modest news or single-client developments. The business depends on a relatively concentrated set of healthcare provider and supplier relationships, so the loss of a significant account could weigh on results. Slower adoption of home infusion programs, reimbursement changes, or broader sector rotation away from healthcare could also compress the multiple.
Technical Picture and Levels to Monitor
The most relevant technical level is the 52-week high near $14.85, which now functions as near-term resistance. A sustained move above that zone would put the stock into record territory and could open the path toward the $17.50 target. On the downside, the stock's roughly 52-week low of $7.29 and the psychological $10 level mark the broad trading range from which the shares have climbed. Because the stock has rallied sharply, support has also shifted higher; the area around $13–$13.70, where the stock consolidated before its recent advance, is a key zone to watch for any pullback.
Investment Horizon and What to Follow
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms can differ, and no single timeline is guaranteed. Investors tracking progress toward $17.50 should watch quarterly earnings and guidance, gross margin trends, and any updates on new or expanded provider contracts. Revisions to analyst estimates and price targets—particularly whether the $15 and $20 views converge—will also matter. Broader healthcare reimbursement news and any shift in small-cap or healthcare-sector sentiment are worth monitoring alongside company-specific results. From what I see, this is important because estimate changes often precede meaningful price moves.
Final Assessment
The $17.50 central target is a calculated average of three analyst price targets spanning $15 to $20, and it sits roughly 19% above the latest price near $14.68. Reaching it would require the stock to break into record territory on continued earnings growth and sustained demand in its infusion and oncology service lines. Support comes from a Strong Buy consensus, improving margins, and strong recent momentum, while the principal obstacles are a demanding valuation, small-cap volatility, and customer concentration. The wide analyst range underscores genuine uncertainty about the pace of growth, so investors should monitor earnings, guidance, and estimate revisions rather than treat $17.50 as a certainty. I’m watching this closely as the next few quarters could clarify the trajectory.
Using AI Tools for Additional Perspective
In my own analysis, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor stocks like this one. The tool applies artificial intelligence to track market conditions, technical behavior, and other factors across thousands of securities, helping identify potential opportunities or shifts in trend. It serves as a practical complement to reviewing analyst targets and fundamentals, allowing for more efficient monitoring of positions over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
Aroon Indicator for INFU shows an upward move is likely
INFU's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 143 similar instances where the Aroon Indicator showed a similar pattern. In 104 of the 143 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on INFU as a result. In 79 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for INFU just turned positive on November 10, 2026. Looking at past instances where INFU's MACD turned positive, the stock continued to rise in 43 of 64 cases over the following month. The odds of a continued upward trend are 67%.
INFU moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where INFU advanced for three days, in 175 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for INFU moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 16 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
INFU broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. INFU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.610) is normal, around the industry mean (4.142). P/E Ratio (32.595) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.817) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of external ambulatory infusion pumps
Industry MedicalNursingServices
Advertisement